Health Bulletin 24/ December/ 2022

Here are the top health stories for the day:

Fully prepared to deal with any eventuality, say Delhi hospitals amid coronavirus scare

Amid concerns over an increase in COVID-19 cases in some countries, hospitals in Delhi have instructed their heads of department to strictly follow COVID guidelines. The hospital said they have fully prepared themselves for any eventuality.

Bond Service term reduced to 5 years, penalty to Rs 25.77 lakh: Haryana releases amended Bond Policy for MBBS students

Amid the continuous protest of the MBBS students, the Haryana Medical Education and Research Department has now released the modified bond service conditions.

As per the modified bond rules, the bond amount has been fixed at Rs 25,77,090 for the male candidates at the Government medical colleges, while the amount is Rs 23,19,381 for the female conditions (10% concession).

In case of the Government Aided Medical College (MAMC, Agroha), the amount of bond for the male and female candidates is Rs 21,90,000 and 19,71,000 respectively.

For more details, check out the link given below:

Bond Service Term Reduced To 5 Years, Penalty To Rs 25.77 Lakh: Haryana Releases Amended Bond Policy For MBBS Students

All MD, MS medicos have to undergo residency in district hospitals for 3 months: NMC mandates implementation

District Residency Programme (DRP) that could not be properly implemented due to the COVID-19 pandemic, has now been made mandatory for all the Postgraduate broad speciality students admitted in 2021 batch onwards.

Writing to the Deans and Principals of all the medical colleges and Directors of Medical Education (DME) of the country, the Postgraduate Medical Education Board (PGMEB) of the National Medical Commission has informed about this.

For more details, check out the link given below:

All MD, MS Medicos Have To Undergo Residency In District Hospitals For 3 Months: NMC Mandates Implementation

Bharat Biotech's intranasal COVID vaccine approved by Govt, to be available on CO-WIN

The central government has approved the use of Bharat Biotech's nasal Covid vaccine iNCOVACC to be included in the country's vaccination programme as a booster dose for those above 18 years of age.

The Union Health Ministry said that those who have taken Covishield and Covaxin can take the nasal vaccine as a heterologous booster dose.

For more details, check out the link given below:

Centre Nod To Bharat Biotech Nasal COVID Vaccine INCOVACC, To Be Availabile In Private Hospitals